DK0901633T3 - Screening af midler til behandling af Alzheimers sygdom - Google Patents

Screening af midler til behandling af Alzheimers sygdom

Info

Publication number
DK0901633T3
DK0901633T3 DK97923188T DK97923188T DK0901633T3 DK 0901633 T3 DK0901633 T3 DK 0901633T3 DK 97923188 T DK97923188 T DK 97923188T DK 97923188 T DK97923188 T DK 97923188T DK 0901633 T3 DK0901633 T3 DK 0901633T3
Authority
DK
Denmark
Prior art keywords
agent
alzheimer
disease
filaments
treatment
Prior art date
Application number
DK97923188T
Other languages
Danish (da)
English (en)
Inventor
Michel Goedert
Ross Jakes
Maria Grazia Spillantini
Masato Hasegawa
Michael John Smith
Richard Anthony Crowther
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Application granted granted Critical
Publication of DK0901633T3 publication Critical patent/DK0901633T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97923188T 1996-05-23 1997-05-20 Screening af midler til behandling af Alzheimers sygdom DK0901633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9610829.5A GB9610829D0 (en) 1996-05-23 1996-05-23 Screening of agents for treatment of azlheimers disease
PCT/GB1997/001356 WO1997044669A1 (fr) 1996-05-23 1997-05-20 Selection d'agents pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
DK0901633T3 true DK0901633T3 (da) 2003-06-16

Family

ID=10794213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97923188T DK0901633T3 (da) 1996-05-23 1997-05-20 Screening af midler til behandling af Alzheimers sygdom

Country Status (10)

Country Link
US (1) US6245575B1 (fr)
EP (1) EP0901633B1 (fr)
JP (1) JP2001503509A (fr)
AT (1) ATE235058T1 (fr)
DE (1) DE69719978T2 (fr)
DK (1) DK0901633T3 (fr)
ES (1) ES2194198T3 (fr)
GB (1) GB9610829D0 (fr)
PT (1) PT901633E (fr)
WO (1) WO1997044669A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5757598A (en) * 1996-12-13 1998-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
WO2004041779A2 (fr) 2002-11-01 2004-05-21 Proteotech, Inc. Induction rapide de la formation de la plaque amyloide d'alzheimer par des glycosaminoglycanes sulfates
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
JP2013032295A (ja) * 2009-12-04 2013-02-14 Kaneka Corp タウ蛋白の吸着材および吸着除去システム
JP2020515846A (ja) * 2017-03-28 2020-05-28 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウタンパク質凝集を調節する化合物の検出のための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
EP0613560B2 (fr) 1991-11-12 2006-06-21 Prana Biotechnology Ltd Procede de diagnostic et de traitement de la maladie d'alzheimer
JPH07507044A (ja) * 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト　ツール　フェルデルング　デル　ヴィッセンシャフテン　エー．ヴェー． アルツハイマー病の診断および治療用の新規な手段
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis

Also Published As

Publication number Publication date
DE69719978D1 (de) 2003-04-24
GB9610829D0 (en) 1996-07-31
PT901633E (pt) 2003-07-31
EP0901633B1 (fr) 2003-03-19
ES2194198T3 (es) 2003-11-16
JP2001503509A (ja) 2001-03-13
DE69719978T2 (de) 2003-12-18
WO1997044669A1 (fr) 1997-11-27
US6245575B1 (en) 2001-06-12
EP0901633A1 (fr) 1999-03-17
ATE235058T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
EE200100645A (et) Amüloidogeense haiguse preventsioon ja ravi
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
BR9909382A (pt) Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
TW264480B (fr)
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
EA200300637A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
ATE214924T1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
DK1160256T4 (da) Monoklonalt antistof der er specifikt for beta-A4 (1-42)-peptid
ATE324119T1 (de) Verwendung von saccharid-konjugaten
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
NO20011891L (no) Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon
DE69735545D1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
RU93004982A (ru) Способ лечения эндотоксинового шока с применением антиадгезивных антител
DK0901633T3 (da) Screening af midler til behandling af Alzheimers sygdom
EP1487854A4 (fr) Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires
DK0871457T3 (da) Isolerede stromaceller og fremgangsmåder til anvendelse heraf
EP1039931A4 (fr) Anticorps de recombinaison multivalents destines au traitement d'infections dues au rhinovirus humain (hrv)
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente